Featured Research

from universities, journals, and other organizations

Blocking nuclear receptor may cut off tumor blood supply

Date:
January 12, 2010
Source:
Baylor College of Medicine
Summary:
A new method of blocking the genesis of blood vessels that feed tumors may start with the nuclear receptor COUP-TFII, said researchers who have studied the factor for more than 20 years.

A new method of blocking the genesis of blood vessels that feed tumors may start with the nuclear receptor COUP-TFII (chicken ovalbumin upstream promoter-transcription factor II), said a pair of Baylor College of Medicine researchers who have studied the factor for more than 20 years.

In a report in the Proceedings of the National Academy of Sciences, a team led by Dr. Ming-Jer Tsai and Dr. Sophia Y. Tsai, both professors of molecular and cellular biology at BCM, described experiments in which the growth of new blood vessels and tumors themselves were suppressed when COUP-TFII was not present.

Their work demonstrates that the receptor directly regulates an angiogenic factor called Angiopoietin-1, which enhances the development of new blood vessels. (Angiogenesis means encouraging the formation of new blood vessels.) Without COUP-TFII, Angiopoietin-1 does not carry out its job efficiently meaning that neither the blood vessels nor the tumors grow, probably because there is limited vasculature to provide nourishment.

"This is important because it means we may be able to find an antagonist that can intervene to halt tumor growth and metastasis," said Dr. Ming-Jer Tsai. "Metastasis is the reason most cancer patients die."

At present, studies of vascular endothelial growth factor (VEGF) inhibitors are underway, he said. This factor also plays an important role in the growth of new blood vessels, and the drugs work against the tumors only for a short while.

"They only work on one pathway of angiogenesis," he said. This finding identifies another important pathway and another way to fight the tumors.

"We studied breast cancer tumors in this model," said Dr. Sophia Tsai. She said the team plans to look at other kinds of solid tumors in which they believe COUP-TFII plays a role in angiogenesis.

Another benefit of knocking out COUP-TFII is that it is not needed in adult animals, she said. COUP-TFII is important in blood vessel formation in the developing fetus but plays no important role in maintaining the vasculature afterward, except in situations such as pregnancy or wound healing. The blood vessels of adult animals that lacked the factor remained normal.

She, Dr. Ming-Jer Tsai and their colleagues are also looking at ways to screen known biological chemicals for the ability to inhibit COUP-TFII.

Others who took part in this work include Drs. Jun Qin, Xinpu Chen and Xin Xie, all postdoctoral associates in the Tsais' laboratories.

Funding for this work came from the National Institutes of Health.


Story Source:

The above story is based on materials provided by Baylor College of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Baylor College of Medicine. "Blocking nuclear receptor may cut off tumor blood supply." ScienceDaily. ScienceDaily, 12 January 2010. <www.sciencedaily.com/releases/2010/01/100111154916.htm>.
Baylor College of Medicine. (2010, January 12). Blocking nuclear receptor may cut off tumor blood supply. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/01/100111154916.htm
Baylor College of Medicine. "Blocking nuclear receptor may cut off tumor blood supply." ScienceDaily. www.sciencedaily.com/releases/2010/01/100111154916.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins